Year-end Sale % OFF 
Abstract
The purpose of this study was to determine the effect of microRNA (miR)-556-3p on cell proliferation and apoptosis of hemangioma-derived endothelial cells (HemECs). qRT-PCR was used to compare the expressions of miR-556-3p in HemECs and normal cells. The target gene was identified using dual-luciferase reporter assay. Cell proliferation was measured with MTT assay, while western blotting was used to assay VEGFC expression levels. Apoptosis was assayed with FITC Annexin V Apoptosis assay kit. miR-556-3p was overexpressed in HemECs. Transfection with miR-556-3p inhibitor resulted in decreased proliferation of HemECs (p<0.05). The expression of the target gene of miR-556-3pi.e. VEGFC was upregulated when miR-556-3p inhibitor was transfected. The transfection also resulted in increased apoptosis. In HemECs, miR-556-3p is overexpressed and VEGFC expression is low. Thus, miR-556-3p or VEGFC might be potential targets for treatment of angiosarcoma.
Highlights
Infantile hemangioma (IH), the most diagnosis tumor of infancy, typically appears in the second week of life [1]
The purpose of this study was to determine the effect of microRNA-556-3p on cell proliferation and apoptosis of hemangioma-derived endothelial cells (HemECs). qRT-PCR was used to compare the expressions of miR-556-3p in HemECs and normal cells
Apoptosis was assayed with FITC Annexin V Apoptosis assay kit. miR-556-3p was overexpressed in HemECs
Summary
Infantile hemangioma (IH), the most diagnosis tumor of infancy, typically appears in the second week of life [1]. This tumor is usually benign, and may be ignored because most patients usually recover, but some patients with serious complications require treatment [2]. MiR-143 inhibited tumor cell proliferation in multiple cancer types such as esophageal squamous cell carcinoma and glioblastoma [10]. In spite of these studies, there is need for more investigation on the effect of miR-556-3p in the growth of hemangioma
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
